Meet the 2024 FAST Spring cohort, comprised of twelve innovative startups focused on promising developments in therapeutics and medical technology. These companies will spend the next several weeks working with our curated network of advisors to develop a compelling commercialization strategy. Join them June 25 at our Innovation Showcase, where these founders will present to an audience of investors and collaboration partners.

Join us on June 25 for our Innovation Showcase at Bakar Labs. Learn more, here!

Acrobat Genomics

Acrobat Genomics is pioneering the next generation of safe and effective genetic medicines.

CEO / Co-Founder: Nick Hughes Ph.D.
Email: [email protected]

Anviron

Anviron is an early-stage maker of solid tumor oncology therapeutics. Our team is developing a pipeline of drug candidates that target cancer stem cells and drug resistance in advanced cancers. We have a promising pipeline, successful in vivo proof of concept models and strong, global patents through the late 2030’s.

CEO / Co-Founder: Bradley Morrison, MBA
Email: [email protected]

Arteri

Arteri is a reliable microsystem for consistent blood pressure monitoring.

CEO / Founder: Yu-Guang Yuan
Email: [email protected]

Califia Pharma, Inc.

Califia Pharma is a clinical stage therapeutics company developing a breakthrough therapy for the safe and effective treatment of metastatic drug-resistant cancers.
CEO / Founder: Michael J. Kelner, MD, MS
Email: [email protected]

CDR3 Therapeutics, Inc.

CDR3 is developing a blood stem cell-based therapy to treat HPV-associated cancers, which overcomes the limited persistence of current peripheral blood T cells harvested from the patient, by performing gene therapy on patient stem cells that engraft in the patient’s bone marrow, leading to persistent development of fully functional T cells targeting the cancer.
CEO / Founder: Matthew C. Lorence, Ph.D., MBA
Email: [email protected]

Humanity Neurotech

Humanity Neurotech is developing a brain therapy that uses magnetic fields to treat neuroinflammation in neurological and psychiatric diseases.
CEO / Founder: Blake Gurfein, Ph.D.
Email: [email protected]

Immoon Therapeutics

Immoon Therapeutics is a pre-clinical stage biotech company developing first-in-class small molecule inhibitors to treat B-cell driven diseases such as non-Hodgkin lymphomas (NHL) and autoimmune conditions.
CEO / Founder: Nataliya Yeremenko, Ph.D.
Email: [email protected]

Kofimi Technology, Inc.

Kofimi Technology, Inc is a health technology company that delivers innovative, bias-free patient monitoring devices for adults and children.

CEO / Co-Founder: Valencia Koomson, Ph.D.
Email: [email protected]

Orphagen Pharmaceuticals, Inc.

Orphagen Pharmaceuticals is a pioneer in the discovery of small molecules that modulate unexplored members of the nuclear receptor family. Its most advanced asset is an IND-ready antagonist to the orphan nuclear receptor SF-1 for treatment of adrenocortical cancer (ACC) and significant expansion indications in oncology.

CEO / Founder: Scott Thacher, Ph.D.
Email: [email protected]

Sayenza Biosciences

Sayenza Biosciences is developing a multifunctional, fully automated platform that processes liposuction fat, the largest source of regenerative cells, for limitless aesthetic surgery & regenerative medicine applications.

CEO / Founder: Derek Banyard, MD, MS, MBA
Email: [email protected]

Sphinxion Therapeutics

Sphinxion harnesses scientific achievements to advance options for patients without them.

CEO / Founder: Julie Saba, MD, Ph.D.
Email: [email protected]

VIAN Therapeutics

VIAN Therapeutics pioneers topical peptide drugs for retinal diseases, revolutionizing treatment with non-invasive and convenient eyedrops containing a potent small peptide with exceptional penetration and a novel mechanism to target angiogenesis.

CEO / Founder: Juan Pablo Robles, Ph.D.
Email: [email protected]